|
1
|
Japanese Gastric Cancer Association:
Japanese Classification of Gastric Carcinoma - 2nd English edition.
Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Youn HG, An JY, Choi MG, Noh JH, Sohn TS
and Kim S: Recurrence after curative resection of early gastric
cancer. Ann Surg Oncol. 17:448–454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Saka M, Katai H, Fukagawa T, Nijjar R and
Sano T: Recurrence in early gastric cancer with lymph node
metastasis. Gastric Cancer. 11:214–218. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sano T, Sasako M, Kinoshita T and Maruyama
K: Recurrence of early gastric cancer. Follow-up of 1475 patients
and review of the Japanese literature. Cancer. 72:3174–3178. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Namikawa T, Kitagawa H, Iwabu J, et al:
Clinicopathological properties of the superficial spreading type
early gastric cancer. J Gastrointest Surg. 14:52–57. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ono H, Kondo H, Gotoda T, et al:
Endoscopic mucosal resection for treatment of early gastric cancer.
Gut. 48:225–229. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gotoda T: Endoscopic resection of early
gastric cancer. Gastric Cancer. 10:1–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song KY, Hyung WJ, Kim HH, et al: Is
gastrectomy mandatory for all residual or recurrent gastric cancer
following endoscopic resection? A large-scale Korean multi-center
study. J Surg Oncol. 98:6–10. 2008. View Article : Google Scholar
|
|
9
|
Nagano H, Ohyama S, Fukunaga T, et al:
Indications for gastrectomy after incomplete EMR for early gastric
cancer. Gastric Cancer. 8:149–154. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee HJ, Jang YJ, Kim JH, et al: Clinical
outcomes of gastrectomy after incomplete EMR/ESD. J Gastric Cancer.
11:162–166. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishida M, Morita S, Saka M, Fukagawa T,
Taniguchi H and Katai H: Metachronous liver metastasis from early
gastric cancer. J Gastrointest Surg. 16:837–841. 2012. View Article : Google Scholar
|
|
12
|
Hyung WJ, Lee JH, Choi SH, Min JS and Noh
SH: Prognostic impact of lymphatic and/or blood vessel invasion in
patients with node-negative advanced gastric cancer. Ann Surg
Oncol. 9:562–567. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamagata K and Kumagai K: Experimental
study of lymphogenous peritoneal cancer dissemination: migration of
fluorescent-labelled tumor cells in a rat model of mesenteric lymph
vessel obstruction. J Exp Clin Cancer Res. 19:211–217. 2000.
|
|
14
|
Hofmann M, Stoss O, Shi D, et al:
Assessment of a HER2 scoring system for gastric cancer: results
from a validation study. Histopathology. 52:797–805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grabsch H, Sivakumar S, Gray S, Gabbert HE
and Müller W: HER2 expression in gastric cancer: rare,
heterogeneous and of no prognostic value - conclusions from 924
cases of two independent series. Cell Oncol. 32:57–65.
2010.PubMed/NCBI
|
|
16
|
Barros-Silva JD, Leitão D, Afonso L, et
al: Association of ERBB2 gene status with histopathological
parameters and disease-specific survival in gastric carcinoma
patients. Br J Cancer. 100:487–493. 2009. View Article : Google Scholar
|
|
17
|
Park DI, Yun JW, Park JH, et al: HER-2/neu
amplification is an independent prognostic factor in gastric
cancer. Dig Dis Sci. 51:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim KC, Koh YW, Chang HM, et al:
Evaluation of HER2 protein expression in gastric carcinomas:
comparative analysis of 1,414 cases of whole-tissue sections and
595 cases of tissue microarrays. Ann Surg Oncol. 18:2833–2840.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boku N, Yamamoto S, Fukuda H, et al:
Fluorouracil versus combination of irinotecan plus cisplatin versus
S-1 in metastatic gastric cancer: a randomised phase 3 study.
Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastrooesophageal junction cancer (ToGA): a phase 3, open-label,
randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
|
|
22
|
Boekhout AH, Beijnen JH and Schellens JH:
Trastuzumab. Oncologist. 16:800–810. 2011. View Article : Google Scholar
|
|
23
|
Sakamoto Y, Sano T, Shimada K, et al:
Favorable indications for hepatectomy in patients with liver
metastasis from gastric cancer. J Surg Oncol. 95:534–539. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Munekage M, Okabayashi T, Hokimoto N, et
al: A case with synchronous multiple liver metastases from gastric
carcinoma: postoperative long-term disease-free survival.
Langenbecks Arch Surg. 394:749–753. 2009. View Article : Google Scholar : PubMed/NCBI
|
